- Home
- SCSC vs ARVN Comparison
SCSC vs ARVN Comparison
Compare SCSC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCSC
- ARVN
- Stock Information
- Founded
- SCSC 1992
- ARVN 2015
- Country
- SCSC United States
- ARVN United States
- Employees
- SCSC N/A
- ARVN N/A
- Industry
- SCSC Retail: Computer Software & Peripheral Equipment
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- SCSC Technology
- ARVN Health Care
- Exchange
- SCSC Nasdaq
- ARVN Nasdaq
- Market Cap
- SCSC 892.3M
- ARVN 740.5M
- IPO Year
- SCSC 1994
- ARVN 2018
- Fundamental
- Price
- SCSC $39.53
- ARVN $11.60
- Analyst Decision
- SCSC Hold
- ARVN Buy
- Analyst Count
- SCSC 1
- ARVN 23
- Target Price
- SCSC $43.00
- ARVN $17.80
- AVG Volume (30 Days)
- SCSC 167.5K
- ARVN 3.0M
- Earning Date
- SCSC 11-06-2025
- ARVN 11-05-2025
- Dividend Yield
- SCSC N/A
- ARVN N/A
- EPS Growth
- SCSC 1.79
- ARVN N/A
- EPS
- SCSC 3.20
- ARVN N/A
- Revenue
- SCSC $3,004,880,000.00
- ARVN $312,300,000.00
- Revenue This Year
- SCSC $6.48
- ARVN N/A
- Revenue Next Year
- SCSC $4.66
- ARVN N/A
- P/E Ratio
- SCSC $12.35
- ARVN N/A
- Revenue Growth
- SCSC N/A
- ARVN 93.86
- 52 Week Low
- SCSC $28.75
- ARVN $5.90
- 52 Week High
- SCSC $53.90
- ARVN $27.00
- Technical
- Relative Strength Index (RSI)
- SCSC 42.80
- ARVN 58.83
- Support Level
- SCSC $37.36
- ARVN $10.95
- Resistance Level
- SCSC $40.24
- ARVN $14.22
- Average True Range (ATR)
- SCSC 1.67
- ARVN 0.89
- MACD
- SCSC -0.24
- ARVN 0.07
- Stochastic Oscillator
- SCSC 59.13
- ARVN 46.06
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.